Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine /醫學院
  3. Institute of Medicine/醫學研究所
  4. 社區中接受不同抗精神病藥物治療方式的思覺失調症患者之結果差異
 
  • Details
Options

社區中接受不同抗精神病藥物治療方式的思覺失調症患者之結果差異

Date Issued
2021
Author(s)
朱柏全  
Po-Chung Ju  
Advisor
楊順發
Yang Shun Fa  
URI
https://handle.ncl.edu.tw/11296/h7t3w8
https://scholars.csmu.edu.tw/handle/123456789/36596
Abstract
本研究的目的是評估社區中思覺失調症患者在居家照護治療中,其用藥方式之差異與治療效果之間的關係。從全民健康保險研究資料庫取西元2004年至2009年ICD-9-CM診斷碼為295住院之個案為研究對象。研究對象為精神科患者,出院返回社區加入居家照護計畫並給予藥物治療。以長效針劑及口服藥物的病人來比較不同用藥策略所產生的治療差異,包含新一代(risperidone理思必妥)及傳統長效針劑(定義為長效針劑組)或口服抗精神病藥(定義為口服藥物組)。此研究的最終樣本數包含長效針劑組810位個案及口服藥物組945位個案。在控制病人、醫院特性及傾向分數,本研究採取邏輯迴歸統計方法,檢測在12個月的觀察期中,病患採取長效針劑治療對再住院風險的影響與使用口服抗精神病藥物方式有無差異。結果發現長效針劑組比口服藥物組在「再住院」風險的勝算比,校正前為0.80(信賴區間[CI],0.65-0.98)。校正過後的勝算比下降至0.78(信賴區間[CI], 0.63-0.97)。校正傾向分數後,統計結果維持不變。顯示社區思覺失調症患者在居家照護治療中,選擇使用長效針劑治療的病人,與選擇使用口服抗精神病藥物比較,顯示長效針劑組的「精神科再住院率」較低,在預防復發上有較佳的效果。因此,社區中居家治療的思覺失調症患者若使用長效針劑治療,不論選擇新一代或傳統長效針劑,皆能降低病患再住院的風險與復發,預期能降低照護者負擔,可為臨床、醫療支出、社會及經濟帶來莫大助益。
This study is to evaluate the relationship between medication and treatment effectiveness in a home-care setting among patients with schizophrenia. Patients with schizophrenia hospitalized between 2004 and 2009 with a primary International Classification of Diseases, Ninth Revision, Clinical Modification code of 295, were identified from Psychiatric Inpatient Medical Claims Data released by the National Health Research Institute in Taiwan. Patients who joined the home-care program after discharge and were prescribed long-acting injections (LAI), including risperidone long-acting injections and conventional long-acting injections (the LAI group) or oral antipsychotic medications (the oral group) were included as study subjects. The final sample for the study included 810 participants in the LAI group and 945 in the oral group. Logistic regression was performed to examine the independent effect of LAI medication on the risk for re-hospitalization. The unadjusted odds ratio (OR) for re-hospitalization risk was 0.80 (confidence interval [CI], 0.65-0.98) for the LAI group compared to the oral group. Consequently, LAI home-based treatment for the prevention of schizophrenia relapse may lead to substantial clinical and economic benefits in the community.
Subjects
居家治療
邏輯迴歸
新一代長效針劑
傳統長效針劑
理思必妥
思覺失調症
home care
logistic regression
long-acting injections
schizophrenia
Type
thesis
File(s)
No Thumbnail Available
Name

109CSMU5534030-001.zip

Size

1.6 MB

Format

Unknown

Checksum

(MD5):faeb5089a49e2b398982c2297a9364aa

Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback